Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.
about
Blood pressure control for diabetic retinopathyTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusInsulin and glucose-lowering agents for treating people with diabetes and chronic kidney diseaseGlucose targets for preventing diabetic kidney disease and its progressionGlucose lowering therapies for chronic kidney disease and kidney transplantationTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusEnhanced glucose control for preventing and treating diabetic neuropathyTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusEffect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trialsStandards of medical care in diabetes--2012Current Challenges in Diabetic Nephropathy: Early Diagnosis and Ways to Improve OutcomesRecent Advances in Diagnostic Strategies for Diabetic Peripheral NeuropathyUpdates in diabetic peripheral neuropathyPolypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 DiabetesNephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?New insights from monogenic diabetes for "common" type 2 diabetesGenetic Studies on Diabetic Microvascular Complications: Focusing on Genome-Wide Association StudiesOrigin and therapy for hypertriglyceridaemia in type 2 diabetesKidney disease: new technologies translate mechanisms to cureDiabetic neuropathy: one disease or two?Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-AnalysisPatient-centered care for people living with multimorbidityRole of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetesTherapeutic modalities in diabetic nephropathy: standard and emerging approaches.N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetesDiabetic kidney disease: a report from an ADA Consensus ConferenceDiabetic kidney disease: from physiology to therapeuticsUpdates on the management of diabetes in dialysis patientsDiabetic Macular Edema Pathophysiology: Vasogenic versus InflammatorySodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsImprovements in the Management of Diabetic NephropathyDietary fiber intake is associated with HbA1c level among prevalent patients with type 2 diabetes in Pudong New Area of Shanghai, ChinaThe Relationship between Dyslipidemia and Acute Axonal Function in Type 2 Diabetes Mellitus In VivoStandards of medical care in diabetes--2013New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain.Therapeutic management of diabetic kidney disease.Clinical therapeutic strategies for early stage of diabetic kidney disease.A risk prediction model for smoking experimentation in Mexican American youth.Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial
P2860
Q24186434-3C1A4B49-364F-4673-8116-A5DE4C971A69Q24186667-D3DD9611-3751-42EF-878E-2DE3B133FB0FQ24188192-AC0BD9D1-9B77-4FCE-9B98-ED9AE3592C7AQ24198925-6AA78DF4-768B-4B0E-9D6F-801BBE5F55B7Q24201814-2C62E219-E51B-4FB1-918E-0E653651E0B8Q24202505-7C2343E4-6725-4E9D-882E-93FA1C72FE26Q24202790-D2FD5185-93C2-4928-9562-33BD6CF1A60AQ24236456-6046781F-1628-4971-A9A3-DDED7950EA1FQ24628988-0A3A94CF-9349-4279-8F27-B0462EFCCC20Q24632533-71607A6E-7059-400B-A2D0-2803AD35F303Q26744419-F16AE90D-21DE-442F-8491-70DE95F29E38Q26744423-0D3DE43F-D71C-4779-A6B4-D34D8D354178Q26751252-69C2ED9E-2BE5-4441-BE07-A335E8614205Q26767283-82254135-F6F0-4CDB-A755-4523AED4C9F7Q26777994-1F5C162F-4ECF-41D3-9D40-223AA87C4C11Q26795455-3DA48988-3F2A-4A7B-A6CB-D0B1D3CB7C00Q26801676-1BDFD2DB-E40C-4CAD-AF45-262B2E8F9107Q26824004-A230993F-A49C-4FA7-948A-83E5BC930995Q26825227-516E0559-B78A-4668-9514-863A257CB7B1Q26859955-16C681A9-56F7-4CE3-A5A4-5EBBAD8601C5Q26863404-CB922B1F-34D1-4ADF-8B92-29438084F3D7Q27000743-87D52416-65E4-4012-8D84-1E4C60D58766Q27004274-ECD9013A-9C64-47E7-9C08-A6AAB19548A7Q27007027-4760402B-4C49-48BC-8EC5-3A19DCF3A93AQ27008887-79594CC0-EBD8-444E-9475-4B68A88DC499Q27012546-CE168203-1841-45BD-9A55-0A6424B8D6E3Q27021392-4EE2EF71-74BF-42D0-9BCD-AEE8E22A7E89Q27024782-795298EF-F512-4E60-81AB-CA6CF92AADEAQ28070894-C8236F1A-99D3-4D55-BABF-9BF1A193F924Q28072765-E91393FA-BB6C-40E6-9ACA-0D8ED36C54D3Q28080717-BF811D96-B3FA-4657-9242-9B2DFAC4C4E2Q28484431-449C6DC9-A5A1-439D-9D6E-41E794C72055Q28551366-C7C54C22-83EE-41E1-B791-9B9B889AB993Q29620309-C97D97B3-9F8C-483D-890E-55C18BB90319Q30235132-7904A67A-2C11-4B7C-AD57-BA2CAB8E9CD8Q30362729-EA6A8890-EAD4-4529-9A13-153E74DB1A4FQ30363683-26584FAA-58FD-48EF-8658-08123B73DD7BQ30588859-7AAA603F-547D-4BFB-B07E-8870EC3ABBC9Q30597265-C87E0915-84FE-4E14-905E-DB69AAD9714AQ30651606-146631E4-F9C3-4DC1-A5AA-E9166009FBEE
P2860
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effect of intensive treatment ...... f the ACCORD randomised trial.
@ast
Effect of intensive treatment ...... f the ACCORD randomised trial.
@en
Effect of intensive treatment ...... f the ACCORD randomised trial.
@nl
type
label
Effect of intensive treatment ...... f the ACCORD randomised trial.
@ast
Effect of intensive treatment ...... f the ACCORD randomised trial.
@en
Effect of intensive treatment ...... f the ACCORD randomised trial.
@nl
prefLabel
Effect of intensive treatment ...... f the ACCORD randomised trial.
@ast
Effect of intensive treatment ...... f the ACCORD randomised trial.
@en
Effect of intensive treatment ...... f the ACCORD randomised trial.
@nl
P2093
P2860
P1433
P1476
Effect of intensive treatment ...... f the ACCORD randomised trial.
@en
P2093
ACCORD trial group
Armand Krikorian
Bruce P Hamilton
Byron Hoogwerf
Daniel Weiss
Debra Simmons
Diane Karl
Faramarz Ismail-Beigi
Harris Taylor
Irene Hramiak
P2860
P304
P356
10.1016/S0140-6736(10)60576-4
P407
P577
2010-06-30T00:00:00Z